IDH1 and intrahepatic cholangiocarcinoma: A phase I clinical trial of the IDH1 inhibitor AG-220 (NCT02073994 Agios Pharmaceuticals) is currently underway for a range of solid tumours, including ICC, to investigate the safety, pharmacodynamics and pharmacokinetics of this inhibitor.